Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7030156 | 0.79 | ACACB (0.58) | MEN1KMT2ASMN1; SMN2GAAMAPT | |
| SCHEMBL13902205 | 0.79 | KMT2A (0.39) | MEN1KMT2AALDH1A1POLBCYP2C9 | |
| SCHEMBL7030153 | 0.77 | KMT2A (0.41) | MEN1KMT2AALDH1A1POLBCYP2C9 | |
| SCHEMBL6256079 | 0.76 | MEN1 (0.51) | MEN1KMT2AALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL6254691 | 0.76 | MEN1 (0.51) | MEN1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL18959775 | 0.76 | KMT2A (0.46) | MEN1KMT2AALDH1A1POLBCYP2C9 | |
| SCHEMBL6260255 | 0.75 | MEN1 (0.49) | MEN1KMT2AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL14945611 | 0.73 | ADORA2B (0.54) | MEN1KMT2AALDH1A1POLBCYP2C9 | |
| SCHEMBL18135173 | 0.72 | KMT2A (0.48) | MEN1KMT2AALDH1A1POLBCYP2C9 | |
| SCHEMBL7145713 | 0.70 | MMP13 (0.43) | MEN1KMT2AALDH1A1POLBCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | HARTER WILLIAM GLEN (US) | 2003-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | MMP13, MMP3, MMP25 | MEN1 3056/4885KMT2A 1976/4885ALDH1A1 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.